Financial risk of biopharmaceutical enterprises

下面为大家整理一篇优秀的paper代写范文- Financial risk of biopharmaceutical enterprises，供大家参考学习，这篇论文讨论了生物制药企业的财务风险。随着市场经济的发展以及全球化进程的不断推进，生物制药企业已面临日益激烈的市场竞争和巨大的挑战。由于生物制药行业本身具有的高投入、高收益、高风险的特征，生物制药企业面临着较高的风险性。财务风险管理作为生物制药企业风险管理中的重要环节，能否科学准确地分析并评价财务风险，对企业的可持续发展将产生深远的影响。因此，科学地对财务风险进行分析，构建合理的财务风险管理体系，在此基础之上提出相应的控制与应对措施对企业的可持续发展是十分重要的。

With the development of China's social market economy and the continuous advancement of the globalization process, Chinese biopharmaceutical enterprises are facing increasingly fierce market competition and huge challenges. The new round of health care reform policies have had a far-reaching impact on the development of the biopharmaceutical industry. Due to the characteristics of high investment, high income and high risk in the biopharmaceutical industry, biopharmaceutical enterprises are faced with high risks. As an important link in enterprise risk management, whether the financial risk can be analyzed and evaluated scientifically and accurately will have a far-reaching impact on the sustainable development of enterprises. Therefore, it is very important to scientifically analyze the financial risk, build a reasonable financial risk management system, and put forward the corresponding control and response measures on this basis for the sustainable development of enterprises.

Taking Q biopharmaceutical company as the research object, the general understanding of financial risk management is formed by elaborating relevant concepts and theories of financial risk management. Combined with enterprise's own situation and industry characteristics, selection of nearly five years of financial data, respectively from the aspects of financing, investment, operating three analyze the Q of the company's financial activities, and to identify the related key risks, find Q company financing channels for a single, unreasonable debt maturity structure, inefficient investment management, product technology and low added value, the problem such as inventory, accounts receivable management is weak. Then, the financial risk assessment model of Q biopharmacutical company was established, and the weight of each index was determined by analytic hierarchy process. From the analysis results, it can be seen that the investment risk had the greatest impact on Q company, followed by the operation risk and financing risk. Then, the efficiency coefficient method is used to comprehensively evaluate the financial risk of Q company, and the financial risk evaluation results are analyzed. The results show that the financial risk of Q company is in the middle of heavy alarm zone, most of the evaluation indexes are seriously defective, and the possibility of financial risk is relatively large. Finally, according to the financial risk evaluation results of Q company, the following preventive measures are proposed for the problems arising. First, to establish and improve the financial risk management system; Second, the response to financing risks, including expanding financing channels and ways, reasonable arrangement of debt maturity structure; Third, the corresponding investment risks, including scientific investment management, industrial upgrading; Fourth, the operation risk response, including strengthening accounts receivable management, strengthening inventory management and expanding sales channels.

Biomedicine is related to the national economy and people's livelihood, and it is active in the global high-tech industry. It has become the main force to promote the development of scientific and technological achievements into industrial economy, and it plays a decisive role in the country's economic growth and the improvement of science and technology. More and more developed countries such as Europe and the United States turn their attention to the field of biological economy to ensure its healthy and vigorous development and occupy an important position in the national economy. In April 2012, the federal government of the United States released the national bioeconomy blueprint, which listed bioeconomy as a priority policy area and defined the strategic goal of promoting bioeconomy growth. In the same year, the European Union published the strategy of innovation for sustainable growth: European bioeconomy, which aims to promote the economic transformation of the eu economy towards more use of sustainable renewable resources.

In March 2014, the German federal ministry of food and agriculture released the national bioeconomy policy strategy, which proposed that bioeconomy is one of the main driving forces to promote the international competitiveness of German economy, providing new ideas for the transformation of the economic model based on fossil materials into one based on renewable resources or efficient resources. In Europe and the United States and other developed countries, led by biological economy is more and more important position in the global economy, with the development of economic society and the increasingly fierce market competition, our country should base on its own resource advantages, talent advantage and market advantage, develop the biological economy, seize the opportunity, in the international market competition dominance.

In the outline of the 13th five-year plan for national economic and social development of the People's Republic of China, China pointed out that it is necessary to accelerate breakthroughs in the core technologies of new-generation biomedicine and intelligent manufacturing, and support the development and expansion of new-generation information technology and biotechnology industries. We will vigorously promote innovation and industrialization in the emerging frontier areas of smart systems and precision medicine, and form a number of new growth areas. Implement intelligent manufacturing engineering to promote the development and expansion of biomedicine, high performance medical equipment and other industries.

With the development of China's social market economy and the continuous advancement of the globalization process, Chinese biopharmaceutical enterprises are facing increasingly fierce market competition and huge challenges. The new round of health care reform policies have had a far-reaching impact on the development of the biopharmaceutical industry. On the one hand, enterprises are affected by various internal and external uncertainties; on the other hand, due to the industry characteristics of high investment, high return and high risk, biopharmaceutical enterprises have relatively high risks. Therefore, it is very important to analyze the financial risk reasonably, establish a scientific financial risk management system, and put forward corresponding countermeasures and control measures on this basis for the sustainable development of enterprises.

Q company is a production and operation enterprise in the domestic biopharmaceutical industry. Under the complicated economic environment and medical policy reform, it is faced with unprecedented opportunities and risks that cannot be ignored. With the development of China's economy and society and the promotion of globalization, internationally renowned pharmaceutical companies have set their sights on the Chinese market, gradually entering the Chinese market by establishing cooperative relations with domestic enterprises and setting up factories in China. These world-renowned pharmaceutical companies have strong research and development capacity, adequate financial support, perfect management system and a large number of high-tech talents, and have advantages in technology, equipment, talent, environmental protection and other aspects, which bring great competitive pressure to China's pharmaceutical enterprises.

In this economic situation and external environment, Q biopharmaceutical company's financial situation is not good and financial risks cannot be ignored. If a reasonable financial risk prevention system is not established in time, it may have a greater adverse impact on the business development of the enterprise and hinder its healthy development.

Q biopharmaceutical company was selected as the research object, and its financial data of the past five years were included. Line analysis, for the company's financial risk identification, assessment, and put forward the corresponding response and control measures, designed to help improve Q company enterprise financial situation, promote the enterprise sustainable development and to expand the scale of production, the pursuit of a higher economic and social benefits, as well as the biological pharmaceutical industry enterprises.

Help Q biopharmaceutical company to understand its financial situation more comprehensively, carry out daily management activities reasonably and effectively, and then establish a feasible financial risk warning system to prevent financial risks and avoid losses.

Promote the healthy and stable development of Q biopharmaceutical company. In the face of complex economic environment, it can timely discover internal and external risks, improve the financial situation, improve the market competitiveness of the enterprise, promote the sustainable development of the enterprise, and achieve higher economic and social benefits.

Protect the interests of investors, creditors and other stakeholders of Q biopharmaceutical company. Stakeholders can timely understand the financial status of the company, in case of financial anomalies, timely remind stakeholders, and help them solve problems through enterprise management personnel. In addition, it can provide investors and creditors with more information for reference when making decisions, so as to help investors make scientific and reasonable investments and ensure the safety of their investments, so as to protect their stakeholders.

The first chapter is the introduction, which is mainly about the research background and significance, the main content of the research, and the main methods of the research. Chapter two is a review of relevant theories and researches, mainly including concepts related to financial risk, theoretical framework of financial risk management, research status at home and abroad and literature review. Chapter three is the general situation of Q biopharmaceutical company, introduces the basic situation and industry background of Q biopharmaceutical company, and expounds the financial status of Q biopharmaceutical company. The fourth chapter is the financial risk identification of Q biopharmaceutical company. Firstly, the identification method of Q company's financial risk is introduced. Then, the financial situation of Q company is analyzed from three aspects of financing, investment and operation, and the key risks are identified. Chapter 5 for Q biopharmaceutical company financial risk assessment, using the analytic hierarchy process (ahp) and efficacy coefficient method to evaluate the Q of the company's financial risk, financial risk evaluation index system, established by the use of analytic hierarchy process (ahp) to invite experts rated, determine the financial risk of comprehensive target, then the efficacy coefficient method was applied to comprehensive evaluation of the financial risk of Q company and analyze the results; Chapter six deals with and controls the financial risk of Q biopharmaceutical company. Second, the response to financing risks, including expanding financing channels and ways, reasonable arrangement of debt maturity structure; Third, the corresponding investment risks, including the establishment of scientific investment management, industrial upgrading; Fourth, the operation risk response, including strengthening accounts receivable management, strengthening inventory management and expanding sales channels.

Theoretical research method: the concept of financial risk, financial risk management and other theories to give a description and list out, so as to lock the research focus, not only on the current and financial risk related theories, at the same time combined with the characteristics of the development of enterprises, clear analysis of the financial risk development situation, the status quo is also analyzed.

Literature research method: after extensive reading and browsing of domestic and foreign literature on financial risk, it refers to the successful financial risk management mode to provide reference for the research on financial risk analysis of Q biopharmacutical company. It lays the foundation for this research and analysis.

Case study method: Q biopharmaceutical company as the concrete research Gui object, for the whole company's financial situation, from the viewpoints of both quantitative and qualitative, don't risk in the current financial and industry, also by means of industry data, such as the literature on the concrete analysis of the risk, to the company's financial actual research as the research object.

According to the situation of Q bio-pharmaceutical company and the characteristics of the industry, the financial risk of the company was identified and analyzed. It was found that Q company had problems such as single financing channel, unreasonable debt maturity structure, low investment management efficiency, low product technology and added value, weak inventory and accounts receivable management, etc. Then, the analytic hierarchy process (ahp) is used to establish a financial risk assessment model and conduct a comprehensive evaluation of the financial risk of Q company. From the analysis results, it can be seen that the biggest impact on Q company is the investment risk, followed by the operation risk and financing risk. The financial risk indicators are ranked as return on equity, accounts receivable turnover rate, total assets return rate, asset-liability ratio, sales margin, inventory turnover rate, total assets turnover rate, cash flow liability ratio, quick ratio. Then, the efficiency coefficient method is used to comprehensively evaluate the financial risk of Q company. The results show that the financial risk of Q company is in the middle of heavy alarm zone, most of the evaluation indexes are seriously defective, and the possibility of financial risk is relatively large.

Based on the financial risk evaluation results of Q biopharmaceutical company, the causes of financial risk are further analyzed, and the following preventive measures are proposed for the problems. First, to establish and improve the financial risk management system; Second, the control of financing risk, including the expansion of financing channels and financing methods, reasonable arrangement of debt term structure; Third, the response to investment risks, including scientific investment management, industrial upgrading; Fourth, the operation risk response, including strengthening accounts receivable management, strengthening inventory management and expanding sales channels.

51due留学教育原创版权郑重声明：原创paper代写范文源自编辑创作，未经官方许可，网站谢绝转载。对于侵权行为，未经同意的情况下，51Due有权追究法律责任。主要业务有essay代写、assignment代写、paper代写服务。

51due为留学生提供最好的paper代写服务，亲们可以进入主页了解和获取更多paper代写范文 提供作业代写服务，详情可以咨询我们的客服QQ：800020041。